Background {#Sec1}
==========

Acute respiratory distress syndrome (ARDS) is a clinical syndrome comprising a rapid onset of respiratory failure in patients with risk factors, such as refractory arterial hypoxemia with low reaction to supplemental oxygen and the presence of bilateral infiltrates on radiographic imaging \[[@CR1]\]. To date, the diagnosis of ARDS and acute lung injury (ALI) is mostly based on clinical characterization. Frequently-used criteria are the American European Consensus Conference (AECC) criteria \[[@CR2]\] and the Berlin definition \[[@CR3]\].

As the accuracy of a diagnosis of ARDS based only on the clinical syndrome has been questioned, countless studies have focused on the identification of biomarkers for ARDS. Terpstra et al. conducted a meta-analysis in 2014 focused on plasma biomarkers for ARDS in humans and provided a ranking system for distinguishing the disease from at-risk patients and determining the prognosis \[[@CR4]\]. They reviewed multiple plasma biomarkers for ARDS, ranked by pooled odds ratio (OR). However, they only summarized biomarkers for ARDS in plasma; biomarkers in other fluids, such as bronchoalveolar lavage fluid (BALF), were not evaluated.

BALF and other lung fluids, such as pulmonary edema fluid (PEF), epithelial lining fluid (ELF), and lung aspirational fluid (LAF), are definitive in respiratory disease diagnosis. Since BALF provides a sample closest to the site of the disease process, it reflects the local lung environment directly. In 2017, García-Laorden et al. reported that biomarkers representing epithelial apoptosis, such as Fas and FasL, as well as biomarkers reflecting extracellular matrix injury, such as procollagen peptide III (PCP III) and procollagen peptide I (PCP I), were elevated in ARDS BALF samples \[[@CR5]\]. The aim of the present study was to compare biomarker levels in lung fluid samples among patients with ARDS and the at-risk controls, as well as those of non-survivors versus survivors of ARDS.

Methods {#Sec2}
=======

Data source and study selection {#Sec3}
-------------------------------

We manually searched PubMed, Embase, Wed of Science, and the Cochrane Library for studies on biomarkers for ARDS in lung fluid samples published prior to January 11, 2018. Details of the search strategy are listed in Additional file [1](#MOESM1){ref-type="media"}. We also searched the references of included studies. Two researchers screened and evaluated the eligibility of all studies independently, and a third reviewer intervened whenever there was a disagreement. The inclusion criteria were (1) original research report of adult with or at-risk of ARDS, (2) report of exact values of biomarker concentration in lung fluid related to a clinical outcome (diagnosis of ARDS in at-risk patients and/or mortality of ARDS), (3) description of demographic variables, and (4) written in English. The exclusion criteria were (1) written in languages other than English, (2) not related to ARDS/ALI, (3) not an original research, (4) in vivo/in vitro studies, (5) pediatric studies, (6) biomarker not measured in lung fluid, (7) biomarker used for treatment monitoring, and (8) only one article available for a specific biomarker for no mergeable effect size and low reliability.

Data extraction and quality assessment {#Sec4}
--------------------------------------

We built Excel spreadsheets (Microsoft Corp., Redmond, WA) to extract data from the included studies, and the two researchers finished data extraction independently. The ARDS etiology and the mean or median level and standard deviation (SD) of the biomarker in the lung fluid were obtained. When a biomarker was measured sequentially, only the day 1 measurement was extracted. We extracted lung fluid biomarker levels from different subgroups as follows: patients with ARDS versus critically ill non-ARDS controls and survivors versus non-survivors in patients with ARDS. The mean value of a biomarker's concentration was equal to the median level in this study, and standard error (SE) was converted to SD using an Excel formula. In addition, demographic variables (age, sex, and number of participants for each subgroup), diagnostic criteria for ARDS, ARDS mortality, the moment the lung fluid sample was retrieved, the sample type (BALF/other than BALF), sample retrieval location, and volume of BALF irrigation solution used were recorded. The recovery rate of BALF was also recorded, if provided.

All studies were assessed for quality according to the Quality Assessment of Diagnostic Accuracy Studies Score-2 (QUADAS-2), and the content was tailored according to the guideline of QUADAS-2 \[[@CR6]\]. Details of the tailored QUADAS-2 are listed in Additional file [2](#MOESM2){ref-type="media"}. Risk of bias and an applicability concerns graph/summary was conducted using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK).

Data synthesis and data analysis {#Sec5}
--------------------------------

Meta-analysis was performed with Stata 13.1 (StataCorp LLC, College Station, TX). The ratio of means (RoM) was employed to assess the effect size \[[@CR7]--[@CR9]\]. RoM is the mean value of a biomarker in the ARDS group divided by the mean value in the at-risk group (mean~ARDS~/mean~at-risk~) or the mean value of a biomarker in the non-survivors group divided by the mean value in the survivors group (mean~non-survivor~/mean~survivor~). RoM of each study was log transformed and pooled using the inverse-variance method to gain a pooled, transformed RoM, which was then back-transformed to determine the pooled RoM and 95% confidence interval, using the fixed effect model of the Stata software. The significance level for this meta-analysis model was set at *p* \< .05. Forest plots were provided for biomarkers of which four or more studies were included in this meta-analysis. Biomarkers were ranked according to pooled RoM and statistical significance. We used the *Q* statistic to test the existence of heterogeneity; a *p* value of less than 0.10 was considered significant for heterogeneity. *I*^2^ was employed to assess the proportion of total variability due to heterogeneity. An *I*^2^ value of approximately 25% was regarded as low heterogeneity, 50% as medium, and 75% as high heterogeneity. Publication bias was assessed with Egger's regression test \[[@CR10]\], where a *p* value of less than 0.10 was considered significant for publication bias. Duval and Tweedie's trim and fill was then conducted \[[@CR11]\].

For the biomarkers with a significant RoM and existence of heterogeneity, we performed a subgroup meta-analysis on study type (case-control study versus another study type) or sample type (BALF versus other lung fluid), when three or more studies were included.

Results {#Sec6}
=======

Literature search {#Sec7}
-----------------

The total literature search yielded 1156 articles from the databases as follows: PubMed, 340 articles; Web of Science, 522 articles; Embase, 279 articles; Cochrane Library, 12 articles; and 3 articles from the reference lists of included studies. By reviewing the titles and abstracts, studies were mainly excluded due to the following: in vitro/animal studies (*n* = 434), duplication (*n* = 423), not an original research (reviews, editorials, or case reports, *n* = 90), and biomarkers not related with occurrence or mortality of ARDS (*n* = 30). After the initial screening, 95 articles remained for full-text review. Of these, 25 articles only reported on a specific biomarker, 16 articles contained insufficient data, and 4 articles had no full-text copy available, despite attempts to contact the authors. The remaining 49 articles were used for the meta-analysis \[[@CR12]--[@CR60]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of study selection. ARDS, acute respiratory distress syndrome; ALI, acute lung injury; vs, versus

Study characteristics and quality assessment {#Sec8}
--------------------------------------------

Demographic variables of the included studies are summarized in (Table [1](#Tab1){ref-type="table"}). A total of 49 articles involving 2189 patients were included in this meta-analysis. ARDS/ALI was diagnosed according to the AECC criteria in 71% of the studies. Other criteria, such as edema fluid/plasma protein ratio \[[@CR61]\], lung injury score \[[@CR62]\], Fowler criteria \[[@CR63]\], and clinical criteria, were used along with the AECC criteria. The mean age ranged from 37 to 70 years, mortality rate ranged from 15 to 77%, and lung fluid was collected between 30 min of intubation and 72 h of ARDS diagnosis. As for sample retrieval location, the right middle lobe and lingular lobe were the most common. Other locations were based on abnormal areas identified on chest radiographs, and a blind sampling of BALF was performed in two studies. In regard to sample type, 69% of the studies measured biomarkers in BALF with a certain volume of irrigation solution. Ten articles used pulmonary edema fluid, and four articles measured a biomarker in epithelial lining fluid. Only three articles provided the recovery rate of the irrigation solution; therefore, we could only assume a stable recovery rate between subgroups for this study.Table 1Demographic variablesReferenceBiomarkersDiagnostic criteria for ARDSStudy sizeMale (%)AgeMortality (%)Sample retrieved timeSample retrieved locationSample type (vol. of irrigation solution)Studies related to diagnosis Armstrong \[[@CR14]\]Procollagen peptide IAECC6666.764.6548.5 (nsp.)Within 48 h of ICU admissionRight middle lobeBALF (20 mL\*6) Bersten \[[@CR15]\]Total phospholipidsClinical criteria21np.np.np.Within 7 h of study entrynp.LAF Calfee \[[@CR16]\]Soluble intercellular adhesion molecule-1Clinical criteria6759.8450.6344.79 (hosp mort)Within 4 h of intubationnp.PEF Chollet-Martin \[[@CR18]\]Interleukin-8LIS29np.62.12np.Within 72 h of ARDS diagosisnp.ELFTumor necrosis factor-αInterleukin-6 Conner \[[@CR20]\]Soluble intercellular adhesion molecule-1Clinical criteria+EF/plasma protein27np.np.np.Within 1 h of intubationnp.PEF Delclaux \[[@CR21]\]AlbuminClinical criteria2971.435464.29 (nsp.)np.np.BALF (3\*50mL) El Solh \[[@CR22]\]Plasminogen activator inhibitor-1AECC5143.1436.575.88 (hosp mort)Within 8 h of intubationBlind BALPEF Prabhakaran \[[@CR52]\]Plasminogen activator inhibitor-1AECC51585047 (hosp mort)Within 12h of intubationnp.PEF Song \[[@CR56]\]Plasminogen activator inhibitor-1Clinical criteria33397015 (28-day mort)When patients were suspected to have VAPnp.BALF (20mL\*3) Farjanel \[[@CR23]\]Procollagen peptide IIILIS6160.749.2347.5 (hosp mort)3 days after intubationA subsegmental of middle lobeBALF (3\*50mL)Procollagen peptide IAlbumin Geerts \[[@CR25]\]Club cell proteinAECC2673.151np.Within 12 h of ARDS diagnosisRight middle lobeBALF (50mL\*3)Total protein González-López \[[@CR26]\]Interleukin-8AECC22np.50.131.8 (ICU mort)np.np.BALF (20mL\*3)Matrix metalloproteinases-9Procollagen peptide IIIInterleukin-6Vascular endothelial growth factor Hallgren \[[@CR27]\]AlbuminClinical criteria4066.6746.8725 (nsp.)np.Right middle lobeBALF (3\*20mL) Hamacher \[[@CR28]\]Tumor necrosis factor-αAECC567545.4125.07 (hosp mort)np.np.BALF (nsp.)Soluble TNF-α receptors IITransforming growth factor-β1 Idell \[[@CR29]\]Total proteinClinical criteria16np.np.np.Within 96 h of ARDS diagnosisRight middle lobe/right lower lobe/lingulaBALF (30mL\*5) Jabaudon \[[@CR60]\]Soluble receptor for advanced glycation end productsAECC60556166.67Within 24 h of disease onset.np.LAF Karagiorga \[[@CR32]\]Total proteinClinical criteria3164.5241.4322.58 (nsp.)Within 72 h of ARDS diagnosisnp.BALF (20mL\*6)Platelet activating factor-acetyl cholineTotal phospholipidsTotal phospholipases A2 activity Keane \[[@CR33]\]Interleukin-8AECC9np.np.np.np.np.BALF (nsp.)Procollagen peptide IIIProcollagen peptide I Kurdowska \[[@CR36]\]Interleukin-8LIS26np.np.41.2 (nsp.)Upon ICU admissionRight middle lobeBALF (60mL\*3) Lanchou \[[@CR37]\]Matrix metalloproteinases-9AECC2147.65433.3 (nsp.)Within 24 h of ARDS diagnosisRight middle lobeBALF (20mL\*3)Matrix metalloproteinases-2 Martin \[[@CR44]\]Total proteinAECC69684556 (nsp.)Within 72 h of ARDS diagnosisRight middle lobe/lingulaBALF (30mL\*5) Martin \[[@CR43]\]Soluble receptor for advanced glycation end productsAECC695953.946 (nsp.)np.np.BALF (nsp.) Medford \[[@CR45]\]Vascular endothelial growth factorAECC704059.3738.57 (28-day mort)With 72 h of intubationnp.ELF Miller \[[@CR46]\]Interleukin-8AECC35np.48.54np.Within 30 min of intubationnp.PEF Nakos \[[@CR49]\]Total proteinAECC2176.261np.Within 24 h of intubationRight middle lobe/lingula.BALF (20mL\*6)AlbuminPlatelet activating factor-acetyl cholineTotal phospholipids Nakos \[[@CR48]\]Total proteinAECC1966.674533.33 (nsp.)Within 12 h of intubationnp.BALF (20mL\*6)AlbuminPlatelet activating factor-acetyl cholineTotal phospholipids Nakos \[[@CR47]\]Platelet activating factor-acetyl cholineAECC312955.5432.2 (ICU mort)Upon ARDS diagnosisnp.BALF (20mL\*6)Total phospholipases A2 activity Park \[[@CR51]\]Tumor necrosis factor-αAECC5459.144.6720.1 (nsp.)Within 24 h of ARDS diagnosisRight middle lobe/lingulaBALF (30mL\*5)Soluble TNF-α receptors IIInterleukin-1βInterleukin-6 Pugin \[[@CR53]\]Interleukin-8AECC3154.8448.8757.65 (nsp.)np.blind BALPEFMatrix metalloproteinases-2Procollagen peptide III Ricou \[[@CR55]\]Interleukin-6Clinical criteria+LIS2479.250.533.3 (nsp.)Within 24 h of ARDS diagnosisnp.BALF (nsp.) Stern \[[@CR57]\]Procollagen peptide IIIAECC256467.0860 (30-day mort)Within 72 h of ARDS diagnosisThe abnormal area on the chest radiographyBALF (20mL\*6)AlbuminHepatic growth factor Uchida \[[@CR58]\]Soluble receptor for advanced glycation end productsAECC3357.674351.33 (hosp mort)np.np.PEFStudies related to mortality Adamzik \[[@CR12]\]Tumor necrosis actor-αAECC4768.0944.5336.17 (30-day mort)Within 24 h of ICU admissionnp.BALF (40mL\*4)Total proteinInterleukin-6Interleukin-2Interleukin-1βInterleukin-10 Clark \[[@CR19]\]Procollagen peptide IIIAECC11764.142.7841 (hosp mort)Within 72h of ARDS diagosisRight middle lobe/lingulaBALF (30mL\*5) Frenzel \[[@CR24]\]Interleukin-6AECC4660.96245.7 (28-day mort)Within 96h of intubationRight middle lobe/lingulaBALF (20mL\*5)Interleukin-8Tumor necrosis factor-αInterleukin-1βInterleukin-10 Kondo \[[@CR34]\]Kerbs von Lungren-6AECC3284.3870.131.3 (hosp mort)Within 24 h of ARDS diagnosisRight middle lobeELF Lee \[[@CR38]\]Interleukin-8AECC3151.654.551.6 (28-day mortality)Within 48 h of ARDS diagnosisRight middle lobe/lingularBALF (30mL\*5) Lin \[[@CR41]\]Interleukin-6AECC3969.26843.6 (hosp mort)Within 24h of ARDS diagnosisRight middle lobe/lingulaBALF (20mL\*6)Interleukin-8 Nathani \[[@CR50]\]Kerbs von Lungren-6AECC4257.160.13np.Upon study entryMiddle lobeBALF (50mL\*3) Ishizaka \[[@CR30]\]Kerbs von Lungren-6AECC3877%6832 (hosp mort)Upon onset of ARDSRight middle lobeELFStudies related to diagnosis and mortality Agouridakis \[[@CR13]\]Interleukin-2AECC3474.4247.7927.9 (nsp.)Within 2h of ICU admissionnp.BALF (nsp.) Chesnutt \[[@CR17]\]Procollagen peptide IIIAECC+EF/plasma protein4447.7356.2563.64 (hosp mort)Within 1h of intubationnp.PEF Jorens \[[@CR31]\]Club cell proteinFowler+LIS3588.65542.9 (nsp.)Within 12 h of ARDS diagnosisRight middle lobeBALF (50mL\*3) Kropski \[[@CR35]\]Club cell proteinAECC+EF/plasma protein3246.94856.5 (nsp.)Within 24 h of intubationnp.PEF Lee \[[@CR39]\]IL-8Clinical criteria11278.666.577.3 (nsp)With 24h of ICU admissionThe most abnormal area on the chest radiography/right middle lobe/lingulaBALF (20mL\*6)Tumor necrosis factor-αInterleukin-1βInterleukin-6Interleukin-10 Lesur \[[@CR40]\]Interleukin-2AECC3336.451.5224.2 (hosp mort)Within 72h of intubationRight middle lobe/lingulaBALF (20mL\*5) Marshall \[[@CR42]\]Procollagen peptide IIIAECC6053.3351.3531.67 (nsp.)Within 24h of ARDS diagnosisnp.BALF (nsp.) Quesnel \[[@CR54]\]Interleukin-8AECC12264.86733.6 (28-day mort)np.np.BALF (20mL\*6)Procollagen peptide ITransforming growth factor-β1Hepatic growth factor Ware \[[@CR59]\]Vascular endothelial growth factorAECC10262.84960 (nsp.)np.np.PEF*ARDS* acute respiratory distress syndrome, *AECC* American-European Consensus Conference, *EF* edema fluid, *LIS* lung injury score, *np* not provided, *nsp* not specific, *mort* mortality, *hosp mort* hospital mortality, *ICU* intensive care unit, *BALF* bronchoalveolar lavage fluid, *LAF* lung aspirational fluid, *ELF* epithelial lining fluid, *PEF* pulmonary edema fluid

The ARDS etiologies are summarized in Additional file [3](#MOESM3){ref-type="media"}. The most common cause of ARDS was sepsis (30.87%), followed by pneumonia (23.70%), trauma (10.94%), aspiration (8.53%), transfusion (4.23%), and major surgery (3.47%). Other etiologies included vasculitis, retroperitoneal hematoma-DIC, drug overdose, reperfusion injury, and diabetic ketoacidosis.

The quality assessment is displayed in Additional file [4](#MOESM4){ref-type="media"}, including the risk of bias and applicability of studies to the review question.

Biomarkers associated with ARDS diagnosis {#Sec9}
-----------------------------------------

We performed a meta-analysis on 22 biomarkers in lung fluid associated with the diagnosis of ARDS in the at-risk population (Table [2](#Tab2){ref-type="table"}); Fig. [2](#Fig2){ref-type="fig"} shows the forest plots for biomarkers available in at least 3 studies. Pooled RoM values for total phospholipases A2 activity (total PLA2 activity) (17.995 \[11.381, 28.454\]), total protein (9.299 \[7.575, 11.414\]), albumin (6.544 \[4.908, 8.725\]), plasminogen activator inhibitor-1 (PAI-1) (5.525 \[3.876, 7.877\]), soluble receptor for advanced glycation end products (sRAGE) (4.901 \[3.603, 7.673\]), platelet activating factor-acetyl choline (PAF-AcH) (4.783 \[3.495, 6.545\]), soluble tumor necrosis factor-α receptors II (STNF-RII) (3.253 \[1.765, 5.993\]), hepatic growth factor (HGF) (3.199 \[1.668, 6.135\]), and interleukin-8 (IL-8) (3.008 \[2.322, 3.896\]) were the highest. The overall effect size ranged from 0.548 to 17.995, among biomarkers with significant RoM between subgroups, and decreased Club cell protein (CC16) (0.553 \[0.369, 0.827\]) and matrix metalloproteinases-9 (MMP-9) (0.548 \[0.336, 0.893\]) levels in lung fluid indicated a higher possibility of ARDS diagnosis in the at-risk population. However, a pervasive heterogeneity was displayed.Table 2Biomarkers associated with ARDS diagnosisBiomarkerNo. of studyNo. of patientsRoM (95% CI)*p*Heterogeneity*Q* (*p* value)*I*^2^ (%)Total phospholipases A2 activity2\[[@CR32], [@CR47]\]6217.995 (11.381, 28.454)\< 0.0510.54 (0.001)90.50Total protein5\[[@CR25], [@CR29], [@CR32], [@CR44], [@CR48]\]1799.299 (7.575, 11.414)\< 0.0540.48 (\< 0.1)90.10Albumin5\[[@CR21], [@CR23], [@CR27], [@CR48], [@CR57]\]1916.544 (4.908, 8.725)\< 0.0527.35 (\< 0.1)85.40Plasminogen activator inhibitor-13\[[@CR22], [@CR52], [@CR56]\]1355.525 (3.876, 7.877)\< 0.053.69 (0.158)45.8Soluble receptor for advanced glycation end products3\[[@CR43], [@CR58], [@CR60]\]1624.901 (3.603, 7.673)\< 0.0531.19 (0.000)93.6Platelet activating factor-acetyl choline4\[[@CR32], [@CR47]--[@CR49]\]1204.783 (3.495, 6.545)\< 0.0571.83 (\< 0.1)95.80Soluble TNF-α receptors II2\[[@CR28], [@CR51]\]1103.253 (1.765, 5.993)\< 0.054.95 (0.026)79.80Hepatic growth factor2\[[@CR54], [@CR57]\]1443.199 (1.668, 6.135)\< 0.050.02 (0.892)0Interleukin-87\[[@CR18], [@CR26], [@CR36], [@CR39], [@CR46], [@CR53], [@CR54]\]3773.008 (2.322, 3.896)\< 0.0562.08 (\< 0.1)90.30Soluble intercellular adhesion molecule-12\[[@CR16], [@CR20]\]962.952 (1.902, 4.581)\< 0.050.28 (0.6)0Procollagen peptide I2\[[@CR14], [@CR23]\]1332.949 (1.867, 4.659)\< 0.050.11 (0.743)0.00Interleukin-22\[[@CR13], [@CR40]\]672.761 (1.508, 5.057)0.00117.34 (\< 0.1)94.20Procollagen peptide III6\[[@CR17], [@CR23], [@CR26], [@CR42], [@CR53], [@CR57]\]1952.328 (1.456, 3.723)\< 0.052.81 (0.729)0Interleukin-65\[[@CR18], [@CR26], [@CR39], [@CR51], [@CR55]\]2501.826 (1.170, 2.852)0.0089.1 (0.0059)56Club cell protein3\[[@CR25], [@CR31], [@CR35]\]930.553 (0.369, 0.827)0.0043.6 (0.166)44.40Matrix metalloproteinases-92\[[@CR26], [@CR37]\]430.548 (0.336, 0.893)0.01615.45 (\< 0.1)93.50Transforming growth factor-β12\[[@CR28], [@CR54]\]1161.32 (0.575, 3.034)0.5130.93 (0.334)0Tumor necrosis factor-α4\[[@CR18], [@CR28], [@CR39], [@CR51]\]2471.3 (0.917, 1.843)0.142.97 (0.397)0Matrix metalloproteinases −22\[[@CR37], [@CR53]\]521.066 (0.889, 1.278)0.4930.06 (0.814)0Total phospholipids4\[[@CR15], [@CR32], [@CR48], [@CR49]\]1101.003 (0.862, 1.166)0.97334.25 (\< 0.1)91.20Interleukin-1β2\[[@CR39], [@CR51]\]1660.952 (0.628, 1.444)0.8174.23 (0.04)76.30Vascular endothelial growth factor3\[[@CR26], [@CR45], [@CR59]\]1940.812 (0.544, 1.212)0.3093.4 (0.183)41.20Numbers within the square brackets were reference numbers*RoM* ratio of means, *CI* confident intervalFig. 2Forest plot for acute respiratory distress syndrome (ARDS) diagnosis. RoM, ratio of means; CI, confident interval; IL-6, interleukin-6; IL-8, interleukin-8; PAF-ACH, platelet activating factor-acetyl choline; PCPIII, procollagen peptide III

We performed an influence analysis to examine the sensitivity of the results. Influence analysis showed that the heterogeneity was possibly caused by the limited number of studies. By removing the studies with extreme RoM, we observed a robust effect on the biomarkers. The outcome of the influence analysis is displayed in Additional file [5](#MOESM5){ref-type="media"}.

Subgroup analysis was performed for biomarkers IL-8, total protein, albumin, sRAGE, PAF-AcH, and IL-6. Since most of the included studies were case-control studies, we excluded studies with other design types. Heterogeneity for total protein, albumin, and IL-6 was partly explained. However, heterogeneity for IL-8 was not clarified. Only one article was case-control study; therefore, the source of heterogeneity was not determined for PAF-AcH because of a limited number of study. We also excluded studies with ARDS that was not diagnosed using AECC criteria, which significantly reduced the heterogeneity for IL-6, but not for albumin. In addition, we assumed sample type may be a variable between studies because biomarker measurement in BALF was influenced by recovery rate and dilution. IL-8 remained significantly increased when BALF studies were excluded. As only one article measured biomarkers in lung fluid other than BALF, it was not evaluated. Results of the subgroup analysis are presented in Additional file [6](#MOESM6){ref-type="media"}.

Biomarkers associated with ARDS mortality {#Sec10}
-----------------------------------------

We performed a meta-analysis on 11 biomarkers in lung fluid associated with ARDS mortality (Table [3](#Tab3){ref-type="table"}); Fig. [3](#Fig3){ref-type="fig"} shows the forest plots for biomarkers associated with ARDS mortality. Interleukin-1β (IL-1β) (4.617 \[4.331, 4.921\]), IL-6 (3.882 \[3.270, 4.608\]), IL-8 (3.679 \[3.414, 3.964\]), and Kerbs von Lungren-6 (KL-6) (3.178 \[2.931, 3.446\]) ranked the highest in biomarkers associated with ARDS mortality. The overall effect size ranged from 0.406 to 4.617. Among the biomarkers with a significant difference between survivors and non-survivors, decreased levels of interleukin-2 (IL-2) (0.828 \[0.715, 0.959\]) and CC16 (0.406 \[0.362, 0.405\]) were associated with a high mortality rate. Heterogeneity was displayed for many of the biomarkers, and influence analysis indicated that the heterogeneities were not likely caused by extreme RoM values. Due to the small number of studies, subgroup analysis based on design type or sample type could not be performed. Subgroup analysis for tumor necrosis factor-α (TNF-α) was performed when excluding patients with ARDS not diagnosed using AECC criteria. Results of the subgroup analysis are presented in Additional file [7](#MOESM7){ref-type="media"}.Table 3Biomarkers associated with ARDS mortalityBiomarkerNo. of studyNo. of patientsRoM (95% CI)*p*Heterogeneity*Q* (*p* value)*I*^2^ (%)Interleukin-1β3\[[@CR12], [@CR24], [@CR39]\]1374.617 (4.331, 4.921)\< 0.0511.24 (0.004)82.20Interleukin-64\[[@CR12], [@CR24], [@CR39], [@CR41]\]1763.882 (3.270, 4.608)\< 0.0541.09 (\< 0.1)92.70Interleukin-84\[[@CR24], [@CR38], [@CR39], [@CR41]\]1603.679 (3.414, 3.964)\< 0.0520.59 (\< 0.1)85.40Kerbs von Lungren-62\[[@CR30], [@CR34]\]653.178 (2.931, 3.446)\< 0.050.83 (0.363)0.00Plasminogen activator inhibitor-12\[[@CR52], [@CR56]\]322.085 (2.039, 2.133)\< 0.051.31 (0.252)23.70Tumor necrosis factor-α3\[[@CR12], [@CR24], [@CR39]\]1371.923 (1.656, 2.233)\< 0.0511.47 (0.003)82.60Procollagen peptide III3\[[@CR17], [@CR19], [@CR42]\]1941.714 (1.613, 1.822)\< 0.0534.08 (\< 0.1)94.10Total protein3\[[@CR12], [@CR19], [@CR42]\]2081.667 (1.595, 1.742)\< 0.0582.47 (\< 0.1)97.60Interleukin-22\[[@CR13], [@CR40]\]270.828 (0.715, 0.959)0.0121.49 (0.223)32.70Club cell protein2\[[@CR31], [@CR35]\]370.406 (0.362, 0.405)\< 0.0521.08 (\< 0.1)95.30Interleukin-103\[[@CR12], [@CR24], [@CR39]\]1371.019 (0.922, 1.127)0.70954.54 (\< 0.1)96.30Numbers within the square brackets were reference numbers*RoM* ratio of means, *CI* confident intervalFig. 3Forest plot for acute respiratory distress syndrome (ARDS) mortality. RoM, ratio of means; CI, confident interval; IL-6, interleukin-6; IL-8, interleukin-8

Publication bias {#Sec11}
----------------

Among the biomarkers associated with ARDS, Egger's regression test demonstrated a *p* value of less than 0.10 for IL-6; furthermore, when we adjusted for possible publication bias by Duval and Tweedie's trim and fill, the RoM remained significant for IL-6. Among the biomarkers associated with mortality, no publication bias was noted. The results of the publication bias analysis are presented in Additional file [8](#MOESM8){ref-type="media"}.

Discussion {#Sec12}
==========

In this systematic review and meta-analysis, we summarized the biomarkers related to ARDS diagnosis in the at-risk population and those related to ARDS mortality.

By searching several databases and screening for related articles, 49 studies involving 2189 patients were identified.

We discovered that total protein, albumin, PAI-1, PAF-ACH, sTNFα-RII, HGF, IL-8, PCP I, PCP III, soluble receptor for advanced glycation end products (SRAGE), and IL-6 were significantly increased in the lung fluid of patients with ARDS. Although total PLA2 activity, soluble intercellular adhesion molecule-1 (SICAM-1), IL-2, CC16, and MMP-9 were also significantly different between patients with ARDS and at-risk patients, few studies were included on each of these biomarkers, so the results are unreliable.

IL-1β, IL-6, IL-8, TNF-α, PCPIII, and total protein were significantly increased in lung fluid of patients who died in the ARDS cohort. Furthermore, few studies for KL-6, plasminogen activator inhibitor-1 (PAI-1), IL-2, and CC16 were included, although these biomarkers were significantly different between survivors and non-survivors.

Pioneering work by Terpstra et al. reported on plasma biomarkers for ARDS diagnosis and prognosis. They reported that KL-6, lactate dehydrogenase (LDH), SRAGE, von Willebrand factor (vWF), and IL-8 displayed the highest effect size for ARDS diagnosis, and interleukin-4 (IL-4), IL-2, Angiopoietin-2 (Ang-2), and KL-6 had the highest effect size for ARDS prognosis (assessed by pooled odds ratio). These biomarkers represent pathophysiological processes, which led to the hypothesis that ARDS diagnosis is correlated with tissue damage, whereas ARDS mortality is correlated with systemic inflammation (4). In our meta-analysis, biomarkers for ARDS diagnosis were related to inflammation (IL-8 and IL-6), endothelial injury (SICAM), epithelial injury (SRAGE and HGF), lung fibroproliferation (PCPI and PCPIII), and coagulopathy (PAF-ACH). With regard to ARDS mortality, biomarkers related to inflammation (IL-8, IL-6, and IL-1β), epithelial injury (KL-6), and lung fibroproliferation (PCPIII) were elevated in the lung fluid of patients with ARDS presenting the worst outcomes. Therefore, we assume that, aside from tissue damage and systemic inflammation, lung fibroproliferation is vital in both ARDS diagnosis and prognosis. Several studies on lung biopsy of patients with ARDS showed a strong relationship between fibrosis activity and ARDS mortality \[[@CR64], [@CR65]\].

To our knowledge, this is the first meta-analysis of biomarkers in lung fluid for ARDS. Since lower respiratory tract specimens are now easily obtained, BALF and other lung fluids have become frequently used clinical samples for pulmonary disease diagnosis, secondary to plasma/serum. Since the most intensive physiological processes in ARDS occur in the lung, theoretically, lung fluid can reflect the pathophysiological process differently from other body fluids.

In this analysis, we applied RoM to assess the effect size and to attempt to eliminate the bias caused by dilution of different kinds of lung fluid. For example, edema fluid was completely undiluted, whereas BALF might be quite diluted. This methodology has been proved to be robust and is widely used \[[@CR7]--[@CR9], [@CR66], [@CR67]\].

This systematic review and meta-analysis may prompt further research on ARDS diagnosis and prognosis in many different ways. First, it demonstrates the research priorities and indicates that research on ARDS biomarkers in lung fluid and other compartments is needed. Second, it establishes ARDS biomarkers and their performance in lung fluid as an innovative research field. Third, it identifies numerous novel translational approaches for biomarker measurement in different compartments, such as chromatography for metabolomics separation and mass spectrometry or nuclear magnetic resonance spectroscopy for biomarker detection \[[@CR68]\]. Although some non-quantitative methods were not included in this meta-analysis, they are still worth exploring.

There were limitations in this meta-analysis as well. First, although we performed a subgroup analysis of the biomarkers related to ARDS diagnosis and mortality, heterogeneity was not explainable for every biomarker. We assume that this could be related to the different etiologies of ARDS, variation in BALF procedures between studies, multiple control types used in the studies, wide range of intervals between study inclusion and biomarker measurement, and different treatments for ARDS. We were not able to conduct further analysis due to the limited information.

Second, a limited number of studies were included for each biomarker, which impedes the reproducibility of the results. The number of studies for each biomarker should be taken into consideration while assessing the performance in the ranking system.

Third, only the biomarkers addressed by two or more studies were included. Because of this, promising biomarkers evaluated in a single study were not considered, which may limit the view on lung fluid biomarker research as a whole.

Finally, the use of lung fluid as a study object itself had some limitations. Due to the lack of information on specific BALF procedures, we could only assume the recovery rates between subgroups in one study were within an acceptable range, which may have caused some of the heterogeneity between studies.

Conclusions {#Sec13}
===========

This systematic review and meta-analysis included 49 studies with 2189 participants, providing an overview of research on lung fluid biomarkers for ARDS. The ranking system provided by evaluating the effect size for ARDS diagnosis and prognosis may serve as a reference for further research on biomarkers for ARDS.
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AECC

:   American European Consensus Conference

ALI

:   Acute lung injury

Ang-2

:   Angiopoietin-2

ARDS

:   Acute respiratory distress syndrome

BALF

:   Bronchoalveolar lavage fluid

CC16

:   Club cell protein

ELF

:   Epithelial lining fluid

IL-1β

:   Interleukin-1β

IL-2

:   Interleukin-2

IL-4

:   Interleukin-4

IL-8

:   Interleukin-8

KL-6

:   Kerbs von Lungren-6

LAF

:   Lung aspirational fluid

LDH

:   Lactate dehydrogenase

MMP-9

:   Matrix metalloproteinases-9

OR

:   Odds ratio

PAF-ACH

:   Platelet activating factor-acetyl choline

PAI-1

:   Plasminogen activator inhibitor-1

PCP I

:   Procollagen peptide I

PCP III

:   Procollagen peptide III

PEF

:   Pulmonary edema fluid

PLA2

:   Phospholipases A2

QUADAS-2

:   Quality Assessment of Diagnostic Accuracy Studies Score-2

RoM

:   Ratio of means

SD

:   Standard deviation

SE

:   Standard error

SICAM

:   Soluble intercellular adhesion molecule-1

SRAGE

:   Soluble receptor for advanced glycation end products

STNF-RII

:   Soluble TNF-α receptors II

TNF-α

:   Tumor necrosis factor-α

vWF

:   von Willebrand factor
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